CLEARBRIDGE HEALTH LIMITED

(Company Registration No.: 201001436C)

(Incorporated in the Republic of Singapore)

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE CATALIST RULES

Pursuant to Rule 706A of the Listing Manual Section B: Rules of Catalist ("**Catalist Rules**") of the Singapore Exchange Securities Trading Limited, the Board of Directors (the "**Board**" or "**Directors**") of Clearbridge Health Limited (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to announce the following changes in the Group's structure during the six-month financial period from 1 July 2025 to 31 December 2025.

INCORPORATION OF A SUBSIDIARY IN HONG KONG

On 9 July 2025, CellTrust Bio Singapore Pte. Ltd., a wholly-owned subsidiary of the Company, incorporated a wholly-owned subsidiary in Hong Kong known as Cell Entrust Bio Co. Limited ("**CEB**") (the "**HK Incorporation**").

CEB has an issued and paid-up share capital of 10,000 Hong Kong Dollars and its principal activity is cryopreservation biotechnology.

The HK Incorporation was funded through internal resources and does not have any material impact on the net tangible assets and earning per share of the Group for the financial year ended 31 December 2025.

INTERNAL RESTRUCTURING

On 9 July 2025, Shanghai Kai Zhun Health Management Co. Ltd., a wholly-owned subsidiary of Clearbridge Medical Hong Kong Corporation Limited ("**CBMHK**"), transferred its 100% shareholdings in Red Dot Health Technology (Shanghai) Co. Ltd. ("**RDHT**") to CBMHK (the "**Internal Restructuring**").

The Internal Restructuring does not have any material impact on the net tangible assets and earnings per share of the Group for the financial year ended 31 December 2025.

DEREGISTRATION OF DORMANT SUBSIDIARY IN INDONESIA

PT Clearbridge Medical Indonesia, a dormant subsidiary of the Group incorporated in Indonesia, has been deregistered on 15 July 2025 (the "**Deregistration**").

The Deregistration does not have any material impact on the net tangible assets and earnings per share of the Group for the financial year ended 31 December 2025.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Executive Director and Chief Executive Officer

27 February 2026

---

*This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "**Sponsor**").*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.